Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL783750 | 0.83 | ALDH1A1 (0.44) | GAATSHRALDH1A1LMNAHSD17B10 | |
| SCHEMBL19895678 | 0.81 | GAA (0.39) | GAATSHRALDH1A1LMNA | |
| SCHEMBL29212509 | 0.76 | GAA (0.36) | GAATSHRALDH1A1 | |
| SCHEMBL783715 | 0.76 | ALDH1A1 (0.43) | GAATSHRALDH1A1LMNAHSD17B10 | |
| SCHEMBL2185156 | 0.74 | GAA (0.50) | GAATSHRALDH1A1LMNAHSD17B10 | |
| SCHEMBL28745990 | 0.74 | GAA (0.50) | GAATSHRALDH1A1LMNAHSD17B10 | |
| SCHEMBL11031201 | 0.74 | — | — | |
| SCHEMBL28358909 | 0.74 | GAA (0.50) | GAATSHRALDH1A1LMNAHSD17B10 | |
| SCHEMBL26684 | 0.74 | — | — | |
| SCHEMBL9720156 | 0.74 | GAA (0.50) | GAATSHRALDH1A1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12100804-B2 | Alkali ION conducting plastic crystals | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2024-09-24 | — | — | US | disclosed |
| EP-4350000-A1 | METHOD FOR DETECTING LIVE LACTIC ACID BACTERIA WITH CARBOHYDRATE METABOLISM ACTIVITY | Kabushiki Kaisha Yakult Honsha (JP) | 2024-04-10 | — | — | EP | disclosed |
| US-11695153-B2 | Alkali ion conducting plastic crystals | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230038702-A1 | BRIGHT TARGETABLE RED CA2+ INDICATORS | HOWARD HUGHES MEDICAL INSTITUTE | 2023-02-09 | — | — | US | disclosed |
| US-20220123360-A1 | ALKALI ION CONDUCTING PLASTIC CRYSTALS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2022-04-21 | — | — | US | disclosed |
| US-20210054001-A1 | BRIGHT TARGETABLE RED CA2+ INDICATORS | HOWARD HUGHES MEDICAL INSTITUTE | 2021-02-25 | — | — | US | disclosed |
| US-6184535-B1 | Method of microscopic observation | OLYMPUS OPTICAL CO., LTD. (JP) | 2001-02-06 | — | — | US | disclosed |
| EP-0248854-B1 | NOVEL BISPHOSPHONIC DERIVATIVES, A METHOD FOR THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 1990-04-25 | — | — | EP | disclosed |
| US-4870063-A | Bisphosphonic acid derivatives, their production and use | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 1989-09-26 | — | — | US | disclosed |
| EP-0248854-A1 | NOVEL BISPHOSPHONIC DERIVATIVES, A METHOD FOR THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION. | LEO PHARM PROD LTD (DK) | 1987-12-16 | — | — | EP | disclosed |
| WO-1987003598-A1 | NOVEL BISPHOSPHONIC DERIVATIVES, A METHOD FOR THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 1987-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230038702-A1 | BRIGHT TARGETABLE RED CA2+ INDICATORS | ATP2A2, ATP2A3, CACNB2 | GAA 563/4885TSHR 3164/4885ALDH1A1 2321/4885 |
| US-20210054001-A1 | BRIGHT TARGETABLE RED CA2+ INDICATORS | ATP2A2, ATP2A3, CACNB2 | GAA 563/4885TSHR 3164/4885ALDH1A1 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.